Cargando…
Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-cent...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606971/ https://www.ncbi.nlm.nih.gov/pubmed/34820471 http://dx.doi.org/10.1177/2329048X211055335 |
_version_ | 1784602451788169216 |
---|---|
author | Lim, Guo Yong Chen, Chun Liang Chan Wei Shih, Derrick |
author_facet | Lim, Guo Yong Chen, Chun Liang Chan Wei Shih, Derrick |
author_sort | Lim, Guo Yong |
collection | PubMed |
description | Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-centre, observational, retrospective study involving 20 pediatric patients was conducted. Perampanel was started for three patients with FIRES, achieving seizure cessation in two patients within a day and on days 19 and 32 of illness. Doses used ranged from 4 to 12 mg/day, without any adverse effects reported or discontinuation of therapy. Responder-rate for other drug-resistant epilepsies is 25%. Median time to achieve ≥50% seizure reduction was 80 days (range: 26-326 days). Adverse effect reported in 47% of the patients includes central nervous system-related, and thrombocytopenia. Eight patients discontinued perampanel, because of ineffectiveness or adverse effects. The median time on perampanel before discontinuation was 179 days (range: 94-345 days). Perampanel may be of benefit in pediatrics FIRES and is of utility in other drug-resistant epilepsies. |
format | Online Article Text |
id | pubmed-8606971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86069712021-11-23 Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies Lim, Guo Yong Chen, Chun Liang Chan Wei Shih, Derrick Child Neurol Open Original Research Article Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-centre, observational, retrospective study involving 20 pediatric patients was conducted. Perampanel was started for three patients with FIRES, achieving seizure cessation in two patients within a day and on days 19 and 32 of illness. Doses used ranged from 4 to 12 mg/day, without any adverse effects reported or discontinuation of therapy. Responder-rate for other drug-resistant epilepsies is 25%. Median time to achieve ≥50% seizure reduction was 80 days (range: 26-326 days). Adverse effect reported in 47% of the patients includes central nervous system-related, and thrombocytopenia. Eight patients discontinued perampanel, because of ineffectiveness or adverse effects. The median time on perampanel before discontinuation was 179 days (range: 94-345 days). Perampanel may be of benefit in pediatrics FIRES and is of utility in other drug-resistant epilepsies. SAGE Publications 2021-11-20 /pmc/articles/PMC8606971/ /pubmed/34820471 http://dx.doi.org/10.1177/2329048X211055335 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Lim, Guo Yong Chen, Chun Liang Chan Wei Shih, Derrick Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title | Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title_full | Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title_fullStr | Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title_full_unstemmed | Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title_short | Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies |
title_sort | utility and safety of perampanel in pediatric fires and other drug-resistant epilepsies |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606971/ https://www.ncbi.nlm.nih.gov/pubmed/34820471 http://dx.doi.org/10.1177/2329048X211055335 |
work_keys_str_mv | AT limguoyong utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies AT chenchunliang utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies AT chanweishihderrick utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies |